What is Zacks Research's Forecast for LLY Q1 Earnings?

Eli Lilly and Company (NYSE:LLY - Free Report) - Investment analysts at Zacks Research decreased their Q1 2026 earnings per share (EPS) estimates for Eli Lilly and Company in a report released on Tuesday, April 22nd. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $6.27 for the quarter, down from their prior forecast of $6.30. The consensus estimate for Eli Lilly and Company's current full-year earnings is $23.48 per share. Zacks Research also issued estimates for Eli Lilly and Company's Q2 2026 earnings at $7.29 EPS, Q3 2026 earnings at $8.20 EPS, Q4 2026 earnings at $9.39 EPS and FY2026 earnings at $31.15 EPS.

A number of other analysts have also weighed in on LLY. Citigroup decreased their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price objective for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Truist Financial upped their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Finally, Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research report on Friday, January 17th. Two analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1,017.00.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $25.21 on Friday, reaching $884.94. The stock had a trading volume of 3,395,903 shares, compared to its average volume of 3,444,748. The business's 50 day moving average is $827.69 and its two-hundred day moving average is $817.91. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a market cap of $839.07 billion, a P/E ratio of 75.57, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.13% of the company's stock.

Institutional Trading of Eli Lilly and Company

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. boosted its holdings in shares of Eli Lilly and Company by 5.3% during the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock worth $1,070,698,000 after purchasing an additional 60,306 shares during the period. Invst LLC raised its position in Eli Lilly and Company by 3.5% during the 3rd quarter. Invst LLC now owns 5,552 shares of the company's stock valued at $4,918,000 after purchasing an additional 189 shares during the last quarter. McIlrath & Eck LLC lifted its holdings in Eli Lilly and Company by 3.4% in the 3rd quarter. McIlrath & Eck LLC now owns 481 shares of the company's stock worth $426,000 after buying an additional 16 shares during the period. Virtu Financial LLC grew its position in shares of Eli Lilly and Company by 111.7% in the 3rd quarter. Virtu Financial LLC now owns 6,531 shares of the company's stock worth $5,786,000 after buying an additional 3,446 shares during the last quarter. Finally, SOA Wealth Advisors LLC. increased its stake in shares of Eli Lilly and Company by 2.4% during the third quarter. SOA Wealth Advisors LLC. now owns 864 shares of the company's stock valued at $766,000 after buying an additional 20 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.